person · Reporting owner

High Katherine A

Disclosed activity across 3 companies

Tapewire entity: 39853
SEC CIK: 0001631248

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CRISPR Therapeutics AGCRSP · Entity 3852	Director	June 05, 2026	June 09, 2026
INCYTE CORPINCY · Entity 3182	Director	June 08, 2026	June 10, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CRISPR Therapeutics AG

Report date June 05, 2026 · Filed June 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.84 · Expires 2036-06-05	Direct	13,000	Reported balance After 2026-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-05 · Grant · Acquired 13,000 · Balance 13,000 F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

Filing footnotes · ownership attribution and instrument terms

F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

INCYTE CORP

Report date June 08, 2026 · Filed June 10, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	14,983	Reported balance After 2026-06-08 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-08 · Grant · Acquired 1,642 · Balance 14,983 F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
Non Qualfied Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.64 · Expires 2036-06-07	Direct	6,111	Reported balance After 2026-06-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-08 · Grant · Acquired 6,111 · Balance 6,111 F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

Filing footnotes · ownership attribution and instrument terms

F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.

F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.

F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Spark Therapeutics, Inc.

Report date December 17, 2019 · Filed December 17, 2019

Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-12-17 transaction · row 1 1 source row Row 1 · 2019-12-17 · Other · Disposed 278,834 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.73 · Expires 2029-01-15	Direct	Reported balance After 2019-12-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-12-17 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.55 · Expires 2028-01-17	Direct	Reported balance After 2019-12-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-12-17 · Disposition to issuer · Disposed 23,625 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.17 · Expires 2027-01-17	Direct	Reported balance After 2019-12-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-12-17 · Disposition to issuer · Disposed 15,750 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.44 · Expires 2026-01-04	Direct	Reported balance After 2019-12-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-12-17 · Disposition to issuer · Disposed 13,750 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-12-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-12-17 · Disposition to issuer · Disposed 21,250 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.

F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.

F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 08, 2026 Filed Jun 10, 2026 20:05 UTC	INCYTE CORP INCY · Entity 3182	GrantNon Qualfied Stock Option (right to buy) · Derivative	6,111	$0.00 Strike: $100.64	$0.00	Disclosure SEC source: 0001631248-26-000002 · wk-form4_1781121943.xml · derivative · entry 2 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,111 Underlying: Common Stock · 6,111 shares Expires 2036-06-07 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document
June 08, 2026 Filed Jun 10, 2026 20:05 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	1,642	$0.00	$0.00	Disclosure SEC source: 0001631248-26-000002 · wk-form4_1781121943.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,983 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
June 05, 2026 Filed Jun 9, 2026 21:42 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $51.84	$0.00	Disclosure SEC source: 0001193125-26-264287 · ownership.xml · derivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2036-06-05 F1 · derivative.exercise_date: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting. Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:29 UTC	INCYTE CORP INCY · Entity 3182	GrantNon Qualfied Stock Option (right to buy) · Derivative	9,216	$0.00 Strike: $70.07	$0.00	Disclosure SEC source: 0001628280-25-031007 · wk-form4_1749760172.xml · derivative · entry 2 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,216 Underlying: Common Stock · 9,216 shares Expires 2035-06-09 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document
June 10, 2025 Filed Jun 12, 2025 20:29 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	2,518	$0.00	$0.00	Disclosure SEC source: 0001628280-25-031007 · wk-form4_1749760172.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,341 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 2,518 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
June 05, 2025 Filed Jun 6, 2025 21:30 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $38.57	$0.00	Disclosure SEC source: 0000950170-25-083267 · ownership.xml · derivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option was granted on June 5, 2025 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2025; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2026 Annual General Meeting of Shareholders. Read SEC document
June 12, 2024 Filed Jun 14, 2024 16:16 UTC	INCYTE CORP INCY · Entity 3182	GrantNon Qualfied Stock Option (right to buy) · Derivative	12,517	$0.00 Strike: $59.94	$0.00	Disclosure SEC source: 0000879169-24-000095 · wk-form4_1718381770.xml · derivative · entry 2 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,517 Underlying: Common Stock · 12,517 shares Expires 2034-06-11 F3 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). Read SEC document
June 12, 2024 Filed Jun 14, 2024 16:16 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	2,830	$0.00	$0.00	Disclosure SEC source: 0000879169-24-000095 · wk-form4_1718381770.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,823 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including this grant, this includes an aggregate of 2,830 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document
May 30, 2024 Filed May 31, 2024 20:15 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $54.06	$0.00	Disclosure SEC source: 0000950170-24-067327 · ownership.xml · derivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2034-05-30 F1 · derivative.exercise_date: This option was granted on May 30, 2024 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on May 31, 2024; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2025 Annual General Meeting of Shareholders. Read SEC document
June 14, 2023 Filed Jun 16, 2023 20:00 UTC	INCYTE CORP INCY · Entity 3182	GrantNon-Qualified Stock Option (right to buy) · Derivative	11,294	$0.00 Strike: $61.44	$0.00	Disclosure SEC source: 0001209191-23-037798 · doc4.xml · derivative · entry 2 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,294 Underlying: Common Stock · 11,294 shares Expires 2033-06-13 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). Read SEC document
June 14, 2023 Filed Jun 16, 2023 20:00 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	2,505	$0.00	$0.00	Disclosure SEC source: 0001209191-23-037798 · doc4.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,993 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document
June 08, 2023 Filed Jun 9, 2023 21:36 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $62.59	$0.00	Disclosure SEC source: 0001209191-23-035978 · doc4.xml · derivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: This option was granted on June 8, 2023 with respect to 13,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2023; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2024 Annual General Meeting of Shareholders. Read SEC document
June 15, 2022 Filed Jun 17, 2022 20:01 UTC	INCYTE CORP INCY · Entity 3182	GrantNon-Qualified Stock Option (right to buy) · Derivative	9,124	$0.00 Strike: $68.55	$0.00	Disclosure SEC source: 0001209191-22-037799 · doc4.xml · derivative · entry 2 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,124 Underlying: Common Stock · 9,124 shares Expires 2032-06-14 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). Read SEC document
June 15, 2022 Filed Jun 17, 2022 20:01 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	2,144	$0.00	$0.00	Disclosure SEC source: 0001209191-22-037799 · doc4.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,488 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document
June 09, 2022 Filed Jun 10, 2022 21:43 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $71.70	$0.00	Disclosure SEC source: 0001209191-22-036048 · doc4.xml · derivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Shares · 12,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders. Read SEC document
June 10, 2021 Filed Jun 14, 2021 21:39 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $123.71	$0.00	Disclosure SEC source: 0001209191-21-040296 · doc4.xml · derivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2021 with respect to 10,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2021; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2022 Annual General Meeting of Shareholders. Read SEC document
May 26, 2021 Filed May 28, 2021 11:17 UTC	INCYTE CORP INCY · Entity 3182	GrantNon-Qualified Stock Option (right to buy) · Derivative	8,010	$0.00 Strike: $83.16	$0.00	Disclosure SEC source: 0001209191-21-036409 · doc4.xml · derivative · entry 2 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,010 Underlying: Common Stock · 8,010 shares Expires 2031-05-25 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). Read SEC document
May 26, 2021 Filed May 28, 2021 11:17 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	1,923	$0.00	$0.00	Disclosure SEC source: 0001209191-21-036409 · doc4.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,344 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document
June 11, 2020 Filed Jun 15, 2020 20:37 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $59.70	$0.00	Disclosure SEC source: 0001209191-20-036625 · doc4.xml · derivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2020 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2020 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2021 Annual General Meeting of Shareholders. Read SEC document
May 26, 2020 Filed May 28, 2020 20:36 UTC	INCYTE CORP INCY · Entity 3182	GrantNon-Qualified Stock Option (right to buy) · Derivative	10,514	$0.00 Strike: $98.68	$0.00	Disclosure SEC source: 0001209191-20-032607 · doc4.xml · derivative · entry 2 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,514 Underlying: Common Stock · 10,514 shares Expires 2030-05-25 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). Read SEC document
May 26, 2020 Filed May 28, 2020 20:36 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	1,282	$0.00	$0.00	Disclosure SEC source: 0001209191-20-032607 · doc4.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,421 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document
March 26, 2020 Filed Mar 30, 2020 21:06 UTC	INCYTE CORP INCY · Entity 3182	GrantNon-Qualified Stock Option · Derivative	1,285	$0.00 Strike: $73.05	$0.00	Disclosure SEC source: 0001209191-20-021730 · doc4.xml · derivative · entry 2 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,285 Underlying: Common Stock · 1,285 shares Expires 2030-03-25 F2 · derivative.exercise_date: This option vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). Read SEC document
March 26, 2020 Filed Mar 30, 2020 21:06 UTC	INCYTE CORP INCY · Entity 3182	GrantCommon Stock	139	$0.00	$0.00	Disclosure SEC source: 0001209191-20-021730 · doc4.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139 F1 · shares: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the Amended and Restated 2010 Stock Incentive Plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document
December 17, 2019 Filed Dec 17, 2019 21:43 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Disposition to issuerRestricted Stock Units · Derivative	21,250	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-19-029434 · doc4.xml · derivative · entry 6 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,250 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings). F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings). Read SEC document
December 17, 2019 Filed Dec 17, 2019 21:43 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Disposition to issuerStock Option (Right to Buy) · Derivative	13,750	$0.00 Strike: $40.44	$0.00	Disclosure SEC source: 0000899243-19-029434 · doc4.xml · derivative · entry 5 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,750 shares Expires 2026-01-04 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document
December 17, 2019 Filed Dec 17, 2019 21:43 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Disposition to issuerStock Option (Right to Buy) · Derivative	15,750	$0.00 Strike: $56.17	$0.00	Disclosure SEC source: 0000899243-19-029434 · doc4.xml · derivative · entry 4 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,750 shares Expires 2027-01-17 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document
December 17, 2019 Filed Dec 17, 2019 21:43 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Disposition to issuerStock Option (Right to Buy) · Derivative	23,625	$0.00 Strike: $50.55	$0.00	Disclosure SEC source: 0000899243-19-029434 · doc4.xml · derivative · entry 3 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,625 shares Expires 2028-01-17 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document
December 17, 2019 Filed Dec 17, 2019 21:43 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Disposition to issuerStock Option (Right to Buy) · Derivative	35,000	$0.00 Strike: $42.73	$0.00	Disclosure SEC source: 0000899243-19-029434 · doc4.xml · derivative · entry 2 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2029-01-15 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document
December 17, 2019 Filed Dec 17, 2019 21:43 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	OtherCommon Stock	278,834	$114.50	$31,926,493.00	Disclosure SEC source: 0000899243-19-029434 · doc4.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. Read SEC document
June 11, 2019 Filed Jun 14, 2019 00:49 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $43.52	$0.00	Disclosure SEC source: 0000899243-19-016947 · doc4.xml · derivative · entry 1 High Katherine A · CIK 0001631248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2019 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments. Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	7,875	$0.00 Strike: $50.55	$0.00	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · derivative · entry 19 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,625 Underlying: Common Stock · 7,875 shares Expires 2028-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% vested January 18, 2019 and the remainder vests in equal annual installments over the following three years. Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	15,750	$0.00 Strike: $56.17	$0.00	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · derivative · entry 18 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,750 Underlying: Common Stock · 15,750 shares Expires 2027-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% vested January 18, 2018 and the remainder vests in equal quarterly installments over the following three years. Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	41,247	$0.00 Strike: $40.44	$0.00	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · derivative · entry 17 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 41,247 shares Expires 2026-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% vested Jamuary 5, 2017 and the remainder vests in equal quarterly installments over the following three years. Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	64,160	$0.00 Strike: $68.45	$0.00	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · derivative · entry 16 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,160 shares Expires 2025-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% vested March 16, 2016 and the remainder vested in equal quarterly installments over the following three years. Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	3	$0.00 Strike: $40.44	$0.00	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · derivative · entry 15 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,997 Underlying: Common Stock · 3 shares Expires 2026-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% vested Jamuary 5, 2017 and the remainder vests in equal quarterly installments over the following three years. Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	5,840	$0.00 Strike: $68.45	$0.00	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · derivative · entry 14 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,160 Underlying: Common Stock · 5,840 shares Expires 2025-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% vested March 16, 2016 and the remainder vested in equal quarterly installments over the following three years. Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionStock Option (right to buy) · Derivative	73,249	$0.00 Strike: $3.45	$0.00	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · derivative · entry 13 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 73,249 shares Expires 2024-07-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% vested on May 24, 2015, and the remainder vested in equal quarterly installments over the following three years. Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Tax withholdingCommon Stock	5,367	$113.26	$607,866.42	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · nonDerivative · entry 12 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,834 Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	7,875	$50.55	$398,081.25	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · nonDerivative · entry 11 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Tax withholdingCommon Stock	11,184	$113.26	$1,266,699.84	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · nonDerivative · entry 10 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,326 Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	15,750	$56.17	$884,677.50	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · nonDerivative · entry 9 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Tax withholdingCommon Stock	25,993	$113.26	$2,943,967.18	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · nonDerivative · entry 8 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,760 Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	21,247	$40.44	$859,228.68	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · nonDerivative · entry 7 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 297,753 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Tax withholdingCommon Stock	49,561	$113.26	$5,613,031.06	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · nonDerivative · entry 6 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,506 Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	64,160	$68.45	$4,391,752.00	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · nonDerivative · entry 5 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	3	$40.44	$121.32	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · nonDerivative · entry 4 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	5,840	$68.45	$399,748.00	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · nonDerivative · entry 3 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Tax withholdingCommon Stock	31,653	$113.25	$3,584,702.25	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · nonDerivative · entry 2 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,064 Read SEC document
March 21, 2019 Filed Mar 25, 2019 20:36 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionCommon Stock	73,249	$3.45	$252,709.05	Disclosure SEC source: 0000899243-19-008882 · doc4.xml · nonDerivative · entry 1 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,717 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 18, 2019 Filed Jan 23, 2019 22:15 UTC	Spark Therapeutics, Inc. ONCE · Entity 153045	Exercise / conversionRestricted Stock Units · Derivative	2,250	$0.00	$0.00	Disclosure SEC source: 0001609351-19-000025 · wf-form4_154828171338855.xml · derivative · entry 6 High Katherine A · CIK 0001631248 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 Underlying: Common Stock · 2,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F4 · derivative.exercise_date: On January 18, 2018, the reporting person was granted 9,000 restricted stock units that vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. F4 · derivative.expiration_date: On January 18, 2018, the reporting person was granted 9,000 restricted stock units that vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.